NF-&#954;B activation mediates LPS-or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock.

Sahan-Firat, Seyhan; Temiz-Resitoglu, Meryem; Guden, Demet Sinem; Senol, Sefika Pinar; Sari, Ayse Nihal; Cil, Meltem; Unsal, Demet; Korkmaz, Belma; Tunctan, Bahar; Malik, Kafait U; Buharalioglu, Cuneyt Kemal

NF-κB activation mediates LPS-or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock.

Sahan-Firat, Seyhan; Temiz-Resitoglu, Meryem; Guden, Demet Sinem; Senol, Sefika Pinar; Sari, Ayse Nihal; Cil, Meltem; Unsal, Demet; Korkmaz, Belma; Tunctan, Bahar; Malik, Kafait U; Buharalioglu, Cuneyt Kemal.

Afiliación

Sahan-Firat S; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Temiz-Resitoglu M; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Guden DS; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Senol SP; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Sari AN; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Cil M; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Unsal D; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Korkmaz B; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Tunctan B; Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Malik KU; Department of Pharmacology, College of Medicine, Center for Health Sciences, University of Tennessee, Memphis, Tennessee.
Buharalioglu CK; Department of Pharmacology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Turkey.

Clin Exp Pharmacol Physiol ; 46(2): 173-182, 2019 02.

Article en En | MEDLINE | ID: mdl-30347478

Asunto(s)

Hipotensión/tratamiento farmacológico; Lipopolisacáridos/farmacología; FN-kappa B/metabolismo; Niacinamida/análogos & derivados; Pirimidinas/farmacología; Choque Séptico/tratamiento farmacológico; Quinasa Syk/antagonistas & inhibidores; Zimosan/farmacología; Animales; Ciclooxigenasa 2/metabolismo; Modelos Animales de Enfermedad; Regulación de la Expresión Génica/efectos de los fármacos; Regulación Enzimológica de la Expresión Génica/efectos de los fármacos; Hipotensión/metabolismo; Hipotensión/patología; Inflamación/tratamiento farmacológico; Inflamación/metabolismo; Inflamación/patología; Interleucina-8/metabolismo; Masculino; Inhibidor NF-kappaB alfa/metabolismo; Niacinamida/farmacología; Niacinamida/uso terapéutico; Óxido Nítrico Sintasa de Tipo II/metabolismo; Inhibidores de Proteínas Quinasas/farmacología; Inhibidores de Proteínas Quinasas/uso terapéutico; Pirimidinas/uso terapéutico; Ratas; Ratas Wistar; Factor de Necrosis Tumoral alfa/metabolismo

Palabras clave

BAY61-3606; NF-κB transactivation; Syk; lipopolysaccharide; zymosan

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pirimidinas / Choque Séptico / Zimosan / Lipopolisacáridos / FN-kappa B / Niacinamida / Quinasa Syk / Hipotensión Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Clin Exp Pharmacol Physiol Año: 2019 Tipo del documento: Article País de afiliación: Turquía

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google